Literature DB >> 18435832

Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls.

Agatha A van der Klaauw1, Nienke R Biermasz, Alberto M Pereira, Klaas W van Kralingen, Olaf M Dekkers, Klaus F Rabe, Johannes W A Smit, Johannes A Romijn.   

Abstract

OBJECTIVE: Adults patients previously treated for craniopharyngioma have increased general and physical fatigue compared to healthy controls. This could be related to disturbed sleep patterns. The aim of this study was to compare sleepiness and sleep patterns in those patients to healthy controls and to patients treated for nonfunctioning macroadenomas (NFMA) of the pituitary.
DESIGN: Case-control study. PATIENTS AND METHODS: Sleepiness and sleep patterns were assessed in 27 adult patients [14 men, 8 patients diagnosed at childhood age, mean age of 53 years (range 27-80 year)] after long-term follow-up and compared to 50 healthy controls and 38 age-, gender- and BMI-matched patients with NFMA. We used two validated questionnaires for sleep parameters (Epworth sleepiness score and Münchener Chronotype Questionnaire).
RESULTS: Sleep patterns (onset, sleep timing, duration and rise time) were not statistically different between the three groups. However, daytime sleepiness scores were increased in patients treated for craniopharyngioma compared to healthy controls, but not different from patients with NFMA. Thirty-three percent of patients with craniopharyngiomas had ESS scores above 10 compared to 8% of healthy controls (P = 0.005), indicating severe daytime hypersomnolence. Neither type of surgery, previous radiotherapy, or age at diagnosis influenced the sleepiness scores in patients with craniopharyngioma.
CONCLUSION: Patients treated for craniopharyngioma or NFMA have increased daytime somnolence despite normal sleep patterns, compared to healthy subjects. The results indicate that increased daytime somnolence is a general consequence of large tumours, and/or their treatment, in the hypothalamic/pituitary region, rather than a specific feature of craniopharyngiomas per se.

Entities:  

Mesh:

Year:  2008        PMID: 18435832     DOI: 10.1111/j.1365-2265.2008.03284.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma.

Authors:  J Lipton; J T Megerian; S V Kothare; Y-J Cho; T Shanahan; H Chart; R Ferber; L Adler-Golden; L E Cohen; C A Czeisler; S L Pomeroy
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

2.  Sleep dysfunction in long term survivors of craniopharyngioma.

Authors:  Peter E Manley; Kiera McKendrick; Megan McGillicudy; Susan N Chi; Mark W Kieran; Laurie E Cohen; Sanjeev Kothare; R Michael Scott; Liliana C Goumnerova; Pengling Sun; Wendy London; Karen J Marcus; Scott L Pomeroy; Nicole J Ullrich
Journal:  J Neurooncol       Date:  2012-04-19       Impact factor: 4.130

3.  Sleep Disturbances in Pediatric Craniopharyngioma: A Systematic Review.

Authors:  Ramona Cordani; Marco Veneruso; Flavia Napoli; Natascia Di Iorgi; Claudia Milanaccio; Alessandro Consales; Nicola Disma; Elisa De Grandis; Mohamad Maghnie; Lino Nobili
Journal:  Front Neurol       Date:  2022-05-13       Impact factor: 4.086

Review 4.  Mortality and morbidity in adult craniopharyngioma.

Authors:  Eva Marie Erfurth; Helene Holmer; Sigridur Bara Fjalldal
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

5.  Craniopharyngioma in adults.

Authors:  Flavius Zoicas; Christof Schöfl
Journal:  Front Endocrinol (Lausanne)       Date:  2012-03-29       Impact factor: 5.555

Review 6.  Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update.

Authors:  Andrea Romigi; Tiziana Feola; Simone Cappellano; Michelangelo De Angelis; Giacomo Pio; Marco Caccamo; Federica Testa; Giuseppe Vitrani; Diego Centonze; Claudio Colonnese; Vincenzo Esposito; Marie-Lise Jaffrain-Rea
Journal:  Front Neurol       Date:  2022-02-09       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.